of ditrisarubicin B were studied by the fluorescence titration technique. Ditrisarubicin B bound to calf thymus DNAwith an affinity higher than any we have ever seen among anthracyclines. The apparent association constant (Xapp) of ditrisarubicin B was 2.36 x 108 m"1, which is 22.7 times larger than that of doxorubicin. The apparent number of binding sites (napp) of ditrisarubicin B per nucleotide of DNAwas 0.164, and this value is identical with that of doxorubicin. Betaclamycin A, which has a trisaccharide chain at C-7 but no carbohydrate at C-10 in the aglycone, interacted with DNAto give a jSfapp of 5.92xWm"1and napp of 0.178. These results suggest to us that the high affinity of ditrisarubicin B for DNAis caused by the existence of a glycosidic chain at C-10.
DNAbinding characteristics of ditrisarubicin B were studied by the fluorescence titration technique. Ditrisarubicin B bound to calf thymus DNAwith an affinity higher than any we have ever seen among anthracyclines. The apparent association constant (Xapp) of ditrisarubicin B was 2.36 x 108 m"1, which is 22.7 times larger than that of doxorubicin. The apparent number of binding sites (napp) of ditrisarubicin B per nucleotide of DNAwas 0.164, and this value is identical with that of doxorubicin. Betaclamycin A, which has a trisaccharide chain at C-7 but no carbohydrate at C-10 in the aglycone, interacted with DNAto give a jSfapp of 5.92xWm"1and napp of 0.178. These results suggest to us that the high affinity of ditrisarubicin B for DNAis caused by the existence of a glycosidic chain at C-10.
Ditrisarubicin antibiotics^are newmembersof the anthracycline family which have three hexoses at each of C-7 and C-10. They prolong the survival period of mice bearing leukemia L1210i:> and Scheme 1. are effective against leukemia P388 and also doxorubicin-resistant leukemia P388, as described elsewhere^. Concerning their mechanism of action, they have been shown to inhibit nucleic acid synthesis, especially RNAsynthesis, at low concentrations^. For these reasons we decided to examine the DNAbinding activity of ditrisarubicin B. This ditrisarubicin is shown to bind extremely tightly to calf thymus DNA.Structure-activity relationships are discussed based on the comparative study of an analogue, betaclamycin A, and a space-filling model of the drug-DNA complex.
Materials and Methods

Chemicals
Calf thymus DNAwas purchased from P-L Biochemicals, Milwaukee, Wis., U.S.A. Ditrisarubicin B was prepared by us as described previouslyx). Betaclamycin A was a gift from Sanraku Incorporated Central Research Laboratories, Fujisawa, Japan.
Fluorometric Titration of DNABinding of Anthracyclines
The quenching of anthracycline fluorescence by DNAwas measured in 0.05 m phosphate buffer, pH 7.0, containing 2.5 x 10"7 m doxorubicin or ditrisarubicin B and various concentrations of calf thymus DNA. In the case of determination of binding constants ditrisarubicin B (2.59 x 10~7 m), doxorubicin (2.59x10"6 m), or betaclamycin A (2.59x10~6 m) was mixed with calf thymus DNA varying in amount between 5x10"7 m and 2.5x10~6 m for ditrisarubicin B and 2x10~6 m and 2x 10"5 m for doxorubicin or betaclamycin A. DNAconcentration of 6.66x10~4 m was taken as the end point of quenching. A Hitachi MPF-4 spectrofluorometer with thermostat set at 20°C was used. Excitation wavelength was 500 nm, and fluorescence emission was determined at 550 nmfor ditrisarubicin B and betaclamycin A or at 590 nm for doxorubicin. DNAconcentration was determined spectrophotometrically at 260 nmby using a molar extinction coefficient with respect to nucleotide residues of 6,600 m"1.
The binding data was analyzed by the Scatchard method3).
Results and Discussion
Fluorescence spectral changes of ditrisarubicin B and doxorubicin upon interaction with calf thymus DNAare shown in Fig. 1 . Fluorescence of ditrisarubicin B was much more quenched at lower DNAconcentrations than that of doxorubicin. Therefore, ditrisarubicin B was demonstrated to have higher affinity for DNAthan doxorubicin. The binding parameters of the former were determined by Scatchard plot3) as shown in Fig. 2 . The apparent binding constant (Xapp) and apparent number of binding sites (napp) were obtained from the negative slope and the intercept of the curve with the f axis, respectively. Results of similar analysis for doxorubicin and betaclamycin A, which was carried out to clarify the structure-activity relationship for ditrisarubicin B, are shown in Fig. 3 ; and the mean values of K&ppand napp from several experiments are given in Table 1 . Ditrisarubicin B was equivalent to doxorubicin in the apparent number of binding sites per nucleotide of DNA;however, the jftTapp of ditrisarubicin B was 2.36 x 108 m" 1, which is the highest value ever reported for the binding of any anthracycline to calf thymus DNA.As the Z"app of doxorubicin was 1.04 x 107 m"1 for the same DNAsolution, ditrisarubicin B has apparent affinity for DNA22.7 times higher than doxorubicin. From comparative studies with another anthracycline, betaclamycin A, we propose the strong binding properties of ditrisarubicin B to be attributable to the trisaccharide at C-10 in the aglycone. Structure of betaclamycin A was determined to be 7-(cinerulosyl-2-deoxyfucosylrhodosaminyl)-/?-rhodomycinone by Yoshimoto et al.Q. This anthracycline thus differs from ditrisarubicin B in the absence of a trisaccharide at C-10 and the displacement of cinerulose B at the end of the C-7 sugar chain by cinerulose. The replacement of cinerulose B by cinerulose is not important for biological activities such as cytotoxicity and inhibition of nucleic acid synthesis, as is also the case for aclarubicin (aclacinomycin A) and aclacinomycin B5»6) or cinerubins A and B6). So betaclamycin A is considered to represent an analogue of ditrisarubicin B without a C-10 glycosidic chain. The J5Tapp of betaclamycin A was 5.92 x lO6 m~\ or 39.8 times smaller than that of ditrisarubicin B. However, its napp was 0.178, which was almost equal to the value for ditrisarubicin B. This result suggests that the trisaccharide at C-10 in ditrisarubicin B intensifies the DNAbinding ability of the antibiotic. Structure-DNA binding relationships of other anthracyclines have been studied7~10), but their K&pp's are the same order of magnitude as that of doxorubicin or a lower value. Amongthese anthracyclines none contained a C-10 glycosidic chain. In order to assess the role of the C-10 glycoside in DNAbinding a spacefilling model of the ditrisarubicin B-DNAcomplex was built according to the molecular structure of the complex of daunorubicin and DNAfragment resolved by X-ray analysis11}, where rings B~D of the aglycone were stacked in the direction perpendicular to the base plane, the cyclohexene ring A rested in the minor groove of the double helix and was anchored there by hydrogen-bonding interactions, and the amino sugar filled the minor groove of the double helix without hydrogenbonding. Wang et c/.n) expected that the trisaccharide of cinerubin A and aclarubicin could bind to the right-handed B-DNAdouble helix with their oligosaccharide moiety running along the minor groove to cover several base pairs. Interestingly, it is possible for the two glycosidic chains of ditrisarubicin B to lie along the minor groove upward and downward from an intercalation site. This orientation might contribute to the higher affinity of ditrisarubicin B for DNAcompared with the other anthracyclines.
Structure-activity relationships for ditrisarubicin B and its comprehensive analogues have been studied systematically and will be described elsewhere2}.
